[Effect of methylpyrazole-carboxylic acid on carbohydrate and lipid metabolisms in patients with diabetes mellitus]. 1975

P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar

The effect of 3-methylpyrazole-5-carboxylic acid (MPC) on carbohydrate and lipid metabolisms was studied in 18 patients with diabetes mellitus. In addition to diet 17 patients had basic treatment with sulfonylureas with or without biguanides, one patient was treated with insulin. In all patients carbohydrate metabolism was not well controlled, 14 patients had elevated triglycerides. Following a control period of 2 weeks the patients received increasing doses of MPC in addition to basic treatment (25825825 mg; 50,25,25 mg; 50, 50, 25 mg). Blood samples were taken in the fasting state before the first dose of MPC. Free fatty acids almost doubled under the influence of MPC. This was due to a rebound effect at night following suppression of lipolysis during the day. Blood glucose levels showed a tendency to fall, urinary glucose excretion, separately examined for day and night ,did not change consistently. Triglycerides fell markedly by 25%, but this reduction was not statistically significant. Cholesterol decreased by 5%. 40% of the patients showed an increase in urinary ketone bodies. Body weight did not change. Side effects due to MPC included flushing, gastrointestinal distress and cardiovascular complaints and were observed in 75% of the patients. Due to the high frequency of side effects it does not seem to be worthwhile to further investigate the therapeutic effect of MPC in a larger number of patients with different dosage regimens.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002271 Carbutamide A sulfonylurea antidiabetic agent with similar actions and uses to CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277) Aminophenurobutane,Butylcarbamide,Glybutamide,Sulfaninylbutylurea,Bucarban,Bukarban,Diabetal,Glucidoral,Oranil,Oranyl
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids

Related Publications

P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
December 1965, The Journal of pharmacology and experimental therapeutics,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
January 1970, Khirurgiia,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
June 1976, Sovetskaia meditsina,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
January 1993, Eksperimental'naia i klinicheskaia farmakologiia,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
January 1983, Sangyo igaku. Japanese journal of industrial health,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
January 1959, Deutsches Archiv fur klinische Medizin,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
January 2000, Klinicheskaia meditsina,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
July 1969, Terapevticheskii arkhiv,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
January 1988, Problemy endokrinologii,
P D Lang, and P Wahl, and Ch Hassalacher, and J Vollmar
October 1966, Casopis lekaru ceskych,
Copied contents to your clipboard!